Regulatory bioinformatics for food and drug safety

被引:11
|
作者
Healy, Marion J. [1 ]
Tong, Weida [2 ]
Ostroff, Stephen [3 ]
Eichler, Hans-Georg [4 ]
Patak, Alex [5 ]
Neuspiel, Margaret [6 ]
Deluyker, Hubert [7 ]
Slikker, William, Jr. [2 ]
机构
[1] Food Stand Australia New Zealand, Barton, ACT 2905, Australia
[2] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA
[3] US FDA, Silver Spring, MD 20993 USA
[4] European Med Agcy, London E14 5EU, England
[5] European Comm, Joint Res Ctr, I-21027 Ispra, Varese, Italy
[6] Canadian Food Inspect Agcy, Ottawa, ON, Canada
[7] European Food Safety Author, I-43126 Parma, Italy
关键词
Bioinformatics; Regulatory bioinformatics; Drug safety; Food safety; Regulatory science; GCRSR; GSRS; Next-generation sequencing; Microbiome; Genomics; GLOBAL-SUMMIT;
D O I
10.1016/j.yrtph.2016.05.021
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
"Regulatory Bioinformatics" strives to develop and implement a standardized and transparent bioinformatic framework to support the implementation of existing and emerging technologies in regulatory decision-making. It has great potential to improve public health through the development and use of clinically important medical products and tools to manage the safety of the food supply. However, the application of regulatory bioinformatics also poses new challenges and requires new knowledge and skill sets. In the latest Global Coalition on Regulatory Science Research (GCRSR) governed conference, Global Summit on Regulatory Science (GSRS2015), regulatory bioinformatics principles were presented with respect to global trends, initiatives and case studies. The discussion revealed that datasets, analytical tools, skills and expertise are rapidly developing, in many cases via large international collaborative consortia. It also revealed that significant research is still required to realize the potential applications of regulatory bioinformatics. While there is significant excitement in the possibilities offered by precision medicine to enhance treatments of serious and/or complex diseases, there is a clear need for further development of mechanisms to securely store, curate and share data, integrate databases, and standardized quality control and data analysis procedures. A greater understanding of the biological significance of the data is also required to fully exploit vast datasets that are becoming available. The application of bioinformatics in the microbiological risk analysis paradigm is delivering clear benefits both for the investigation of food borne pathogens and for decision making on clinically important treatments. It is recognized that regulatory bioinformatics will have many beneficial applications by ensuring high quality data, validated tools and standardized processes, which will help inform the regulatory science community of the requirements necessary to ensure the safe introduction and effective use of these applications. Published by Elsevier Inc.
引用
收藏
页码:342 / 347
页数:6
相关论文
共 50 条
  • [41] Avoiding the regulatory capture of the food and drug administration
    Egilman, David S.
    Presler, Amos H.
    Valentin, Claire S.
    ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (07) : 732 - 733
  • [43] Advances in Regulatory Science at the Food and Drug Administration
    Psaty, Bruce M.
    Goodman, Steven N.
    Breckenridge, Alasdair
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (20): : 2103 - 2104
  • [44] PESTICIDE REGULATORY ACTIVITIES OF THE FOOD AND DRUG ADMINISTRATION
    ROE, RS
    AMERICAN JOURNAL OF PUBLIC HEALTH AND THE NATIONS HEALTH, 1965, 55 (07): : 36 - 37
  • [45] Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines
    Hwang, Thomas J.
    Franklin, Jessica M.
    Chen, Christopher T.
    Lauffenburger, Julie C.
    Gyawali, Bishal
    Kesselheim, Aaron S.
    Darrow, Jonathan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18) : 1805 - +
  • [46] US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics
    Eadie, Ashley
    MacGregor, Andrea
    Wallach, Joshua
    Ross, Joseph
    Herder, Matthew
    BMJ EVIDENCE-BASED MEDICINE, 2023, 28 (03) : 151 - 156
  • [47] Artificial intelligence and real-world data for drug and food safety-A regulatory science perspective
    Thakkar, Shraddha
    Slikker, William, Jr.
    Yiannas, Frank
    Silva, Primal
    Blais, Burton
    Chng, Kern Rei
    Liu, Zhichao
    Adholeya, Alok
    Pappalardo, Francesco
    Carvalho Soares, Monica da Luz
    Beeler, Patrick E.
    Whelan, Maurice
    Roberts, Ruth
    Borlak, Jurgen
    Hugas, Martha
    Torrecilla-Salinas, Carlos
    Girard, Philippe
    Diamond, Matthew C.
    Verloo, Didier
    Panda, Binay
    Rose, Miquella C.
    Jornet, Joaquim Berenguer
    Furuhama, Ayako
    Fang, Hong
    Kwegyir-Afful, Ernest
    Heintz, Kasey
    Arvidson, Kirk
    Burgos, Juan Garcia
    Horst, Alexander
    Tong, Weida
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2023, 140
  • [48] Food and Drug Administration Creates Drug Safety Website
    Nahlen, Dawn Drennan
    NEWBORN AND INFANT NURSING REVIEWS, 2009, 9 (01) : E3 - E3
  • [49] The food and drug administration reinforces commitment to drug safety
    Lang, Les
    GASTROENTEROLOGY, 2007, 132 (05) : 1644 - 1644
  • [50] Emerging technologies for food and drug safety
    Slikker, William, Jr.
    de Souza Lima, Thalita Antony
    Archella, Davide
    de Silva Junior, Jarbas Barbosa
    Barton-Maclaren, Tara
    Bo, Li
    Buvinich, Danitza
    Chaudhry, Qasim
    Chuan, Peiying
    Deluyker, Hubert
    Domselaar, Gary
    Freitas, Meiruze
    Hardy, Barry
    Eichler, Hans-Georg
    Hugas, Marta
    Lee, Kenneth
    Liao, Chia-Ding
    Loo, Lit-Hsin
    Okuda, Haruhiro
    Orisakwe, Orish Ebere
    Patri, Anil
    Sactitono, Carl
    Shi, Leming
    Silva, Primal
    Sistare, Frank
    Thakkar, Shraddha
    Tong, Weida
    Valdez, Mary Lou
    Whelan, Maurice
    Zhao-Wong, Anna
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2018, 98 : 115 - 128